| Pulmonary arterial hypertension
Opsumit vs Tyvaso
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Opsumit vs Tyvaso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTyvaso has a higher rate of injection site reactions vs Opsumit based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tyvaso but not Opsumit, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Opsumit
Tyvaso
At A Glance
Oral
Daily
Endothelin receptor antagonist
Oral inhalation
4 times daily
Prostacyclin analogue
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension due to interstitial lung disease
Dosing
Pulmonary arterial hypertension 10 mg once daily orally; doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.
Pulmonary arterial hypertension, Pulmonary hypertension due to interstitial lung disease Initial dose: 3 breaths (18 mcg) per treatment session 4 times daily via the Tyvaso Inhalation System; if not tolerated, reduce to 1-2 breaths. Increase by 3 breaths per session every 1-2 weeks as tolerated to target maintenance dose of 9-12 breaths per session 4 times daily.
Contraindications
- Pregnancy (may cause fetal harm)
- History of hypersensitivity reaction to macitentan or any component of the product
—
Adverse Reactions
Most common (>=3%) anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, urinary tract infection
Serious embryo-fetal toxicity, hepatotoxicity, fluid retention, decrease in hemoglobin
Postmarketing hypersensitivity reactions (angioedema, pruritus, rash), flushing, nasal congestion, liver aminotransferase elevations and liver injury, edema/fluid retention, symptomatic hypotension
Most common (>=4%) Cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, syncope
Serious Decrease in systemic blood pressure, bleeding
Postmarketing Angioedema
Pharmacology
Macitentan is an endothelin receptor antagonist that inhibits binding of ET-1 to both ETA and ETB receptors with high affinity and sustained occupancy in human pulmonary arterial smooth muscle cells; an active metabolite contributes approximately 40% of total pharmacologic activity.
Treprostinil is a prostacyclin analogue whose major pharmacologic actions are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Opsumit
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Tyvaso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Opsumit
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (0/8) · Qty limit (5/8)
Tyvaso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Opsumit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Tyvaso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Janssen CarePath Oral PAH Savings Program: OpsumitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OpsumitView full Opsumit profile
TyvasoView full Tyvaso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.